SATELLITE SYMPOSIA I – V
S U N D A Y – March 16, 2025
16.45-17.45 SATELLITE SYMPOSIUM I (SAT I)
Industry sponsored Satellite (Daiichi Sankyo)
Lecture Hall III (Overflow Rooms: LHs IV+V)
AML Unpacked: Awareness, Management and Latest Trends in Fit Newly Diagnosed Patients
Meeting Objectives:
∎ Review the current treatment landscape for fit patients with newly diagnosed FLT3-mutated AML
∎ Discuss the assessment of fit patients with newly diagnosed AML, looking to novel targets on the horizon
16.45-16:50
Welcome and Introduction
L. Bullinger, Berlin, DE
16:50-17.10
K. Döhner, Ulm, DE. State of the Art: Treatment Landscape for Fit Patients with Newly Diagnosed FLT3-Mutated AML
17:10-17:30
P. Vyas, Oxford. UK. Hot Topics: Assessing Fit Patients with Newly Diagnosed AML – Novel Targets on the Horizon
17:30-17.45
Panel Discussion and Closing – All Faculty
M O N D A Y – March 17, 2025
16:30-17:30: SATELLITE SYMPOSIUM II (SAT II)
Industry sponsored Session (Otsuka Pharma GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
Managing Difficult Decisions in Unfit AML Patients in the Context of the New ELN 2024 Recommendations
16.30-16.50
L. Bullinger, Berlin, DE. Current and Future Treatment Options for Unfit AML Patients
16:50-17.05
E. Jost, Aachen, DE: How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Combination Therapy Beats HMA Monotherapy
17:05-17:25
W. Kirakosow, Mühlheim a.d.R., DE: How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Still Room for HMA Monotherapy?
17:25-17.30
Closing Remarks
18:00-19:00: SATELLITE SYMPOSIUM III (SAT III)
Industry sponsored Satellite (AbbVie Deutschland GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
Exploring Future Treatment Strategies for AML Patients
18:00-18:05
Welcome and Introduction/Chair:
L. Bullinger, Berlin, DE
18:05-18.25
Ch. Röllig, Dresden, DE: Treatment of IC-Ineligible AML Patients – How Can Novel Strategies Improve Clinical Results?
18:25-18:45
Ch. Craddock, Birmingham, UK: Reaching New Heights: Advancing Outcomes for Transplant Patients in AML
18:45-18.55
Panel Discussion and Q&A
All Faculty
18:55-19.00
Closing Remarks
L. Bullinger, Berlin, DE
T U E S D A Y – March 18, 2025
16:15-17:15: SATELLITE SYMPOSIUM IV (SAT IV)
Industry sponsored Satellite (Servier France)
Lecture Hall III (Overflow Rooms LHs IV+V)
Targeting IDH1 Mutations in Front Line AML for the Unfit Patient
16:15-16:20
Gail Roboz, New York, NY, USA: Emerging Induction Strategies in AML
16:20-16:30
Hartmut Doehner, Ulm, DE: Exploring Therapeutic Strategies for IDH1-Mutated Patients
16:30-16:40
Maria Teresa Voso, Rome, I: Molecular Testing- When and How?
16:40-16:50
Lars Fransecky, Kiel, DE: Clinical Case Presentation
16:50-17:00
Michael Kuehn, Mainz, DE: Shaping the Future of AML Care: Clinical Trials for Targeted Therapies
17:00-17:15
Questions and Discussion
All Faculty
17.45-18.45: SATELLITE SYMPOSIUM V (SAT V)
Industry sponsored Session (Amgen GmbH)
Lecture Hall III (Overflow Rooms LHs IV+V)
A New Era: Immunotherapy for Newly Diagnosed B-ALL
17:45-17:50
Welcome and Introduction
M. Subklewe, Munich, DE
17:50-18.15
N. Gökbuget, Frankfurt, DE: Immunotherapy in Frontline Treatment of Ph-negative and -positive B-ALL
18:15-18:40
M. Subklewe, Munich, DE: The Future: SC Application and New Indications
18:40-18.45
Closing Remarks
N. Gökbuget, Frankfurt, DE
#############
MEET-THE-PROFESSOR SESSIONS I and II
M O N D A Y – March 17, 2025
13:00-13:45: MEET-THE-PROFESSOR SESSION (MTP I)
Industry sponsored Session (Astellas Pharma GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
13:00-13:20:
Ch. Röllig, Dresden DE: R/R FLT3m+ AML – Therapy: Today and in the Future
13:20-13:40:
F. Thol, Hannover, DE: Diagnostics in AML
13:40-13:45:
CLOSING REMARKS
T U E S D A Y – March 18, 2025
13:00-13:45: Meet-the-Professor Session (MTP II)
Industry sponsored Session (Jazz Pharmaceuticals)
Lecture Hall III (Overflow Rooms: LHs IV/V)
13:00-13:03:
Welcome and Introduction
L. Bullinger, Berlin, DE
13:03-13:08 :
L. Bullinger, Essen, DE: Long-Term Survival in Older Patients with Poor Prognosis:A Patient Case Study
13:08-13:28:
Th. Schroeder, Essen, DE: Optimizing Transplant Potential in Older Patients: What Does Real-World Data Tell Us?
13:28-13:43:
Audience Q & A
13:43-13:45:
CLOSING REMARKS
L. Bullinger, Berlin, DE
